Abstract Number: PB0070
Meeting: ISTH 2020 Congress
Theme: Arterial Thromboembolism » Cardiovascular Risk Factors
Background: The platelet glycoprotein IIb/IIIa receptor plays an important role in platelets aggregation. The IIIa polypeptide is polymorphic due to a single base change at position 1565, resulting in either leucine or proline at position 33 of the protein. This polymorphism has been investigated in several thrombotic diseases, and suggested to play a role in thrombotic cardiovascular diseases.
Aims: This study aimed to investigate the association between platelet glycoprotein IIIa Leu 33 Pro gent polymorphism and risk of myocardial infarction (MI).
Methods: This was an analytical case-control study, in which a total of 100 patients with confirmed diagnosis of MI, 60 (60%) of them with ST-elevated myocardial infraction (STEMI) and 40 (40%) with non-ST-elevated myocardial infraction (NSTEMI) were enrolled. Further 100 age- and sex- matched apparently healthy volunteers were recruited as a control group. Genomic DNA was extracted from peripheral blood leucocytes by salting out method. The platelet glycoprotein IIIa gene Le 33 Pro polymorphism was analysed using polymerase chain reaction- restriction fragments length polymorphism (PCR-RFLP). The study was approved by scientific research committee, faculty of medical laboratory sciences, Al Neelain University, Khartoum, Sudan. Informed verbal consent was obtained from all participants before sample collection.
Results: The genotype Le/Le was the most frequent in both patients and control groups (44% and 80%) followed by Le/Pro (41% and 10%)) and Pro/Pro (15% and 10%). While the genotypes Le/Le was found to have a protective effect on both types of MI (OR=0.191; 95% CI: 0.094-0.338, P.value: 0.000 and OR=0.205; 95% CI: .093-.452, P.value= 0.000), the genotype Le/Pro was associated with increased risk (~6 folds) of both STEMI and NSTEMI (OR=6.0, 95% CI: 2.609-13.799, P.value= 0.000 and OR=6.652, 95% CI: 2.690-16.45, P.value= 0.000 respectively).
Conclusions: The GP IIIa Le 33 Pro is significantly associated with the risk of both STEMI and NSTEMI.
To cite this abstract in AMA style:
Mohamed Ahmed E, Mohamed Ahmed MA, Alimairi JM. Platelet Glycoprotein IIIa Leu 33 Pro Polymorphism and Susceptibility to ST-segmented and Non-ST-segmented Myocardial Infraction [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/platelet-glycoprotein-iiia-leu-33-pro-polymorphism-and-susceptibility-to-st-segmented-and-non-st-segmented-myocardial-infraction/. Accessed March 21, 2024.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/platelet-glycoprotein-iiia-leu-33-pro-polymorphism-and-susceptibility-to-st-segmented-and-non-st-segmented-myocardial-infraction/